Marina Baretti, MD of Johns Hopkins University recently provided an update on a clinical trial for fibrolamellar patients that intends to leverage the “glutamine addiction” of FLC tumors. The trial, “DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma”, is currently open for patient enrollment at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland.
In the video below, Dr. Baretti provides a brief overview of the study, and discusses recently approved protocol changes which will allow patients to “self-administer” the glutamine antagonist drug (DRP-104) at home. This new ability of study participants to perform the twice-weekly injections of the drug themselves will reduce their need to visit the clinic in Baltimore, and hopefully allow more patients to participate in the trial.
For more information about this study or its recent protocol changes, please visit clinicaltrials.gov (NCT06027086) or contact the clinical trials team at Johns Hopkins at GIClinicalTrials@jhmi.edu.